Objective: Transsphenoidal surgery (TSS) remains the recommended primary treatment for acromegaly. Long-term outcome data are not available for patients treated with gamma knife radiosurgery (STRS) as a primary treatment.
| INTRODUC TI ON
Acromegaly is associated with excess mortality when uncontrolled, with complications including diabetes mellitus, hypertension, cardiomyopathy, obstructive sleep apnoea and increased risk of colorectal carcinoma. 1 Pituitary surgery is the accepted first-line treatment in the vast majority of cases and allows immediate tumour and biochemical control with success rates of around 50% (with macroadenomas) to 90% (with microadenomas). [1] [2] [3] Medical management is usually used for surgical failure or recurrence, but can be used as primary treatment in selected case. 3 Gamma knife radiosurgery (STRS) refers to single-dose radiation treatment using multiple foci of radiation to achieve target cell death, whilst minimizing the radiation dose to normal tissue. The
Endocrine Society Guidelines for the treatment of acromegaly recommend STRS over fractionated radiotherapy provided the tumour target is suitable. The ideal target is a small tumour (<35 mm diameter) in a position that allows <8 Gy radiation dose to the optic apparatus (usually at least 3-5 mm away), and where the tumour is either unsuitable for surgery or where there is persistent or recurrent disease. 1 The gamma knife has a targeting precision of <0.2 mm.
Exceptionally, patients may be offered STRS as a primary treatment for the control of acromegaly. At the National Centre for Stereotactic Radiosurgery, Sheffield, UK, we have treated over 340 patients with pituitary disease using the gamma knife, out of a total of 18 000 patients treated for all cranial diseases. Since there are no previous data specifically detailing the long-term outcomes of patients with acromegaly treated with STRS by the gamma knife as primary treatment, we report our experience with up to 30 years of follow-up where pituitary surgery was either contra-indicated, refused or tumour size permitted such treatment. 
| ME THODS

| Patients and data
A
| Remission criteria
Since there have been changes in the criteria for biochemical remission over the study period, we have adopted two main criteria for disease remission (or control): (a), "Guideline-based control"-normal age-sex-adjusted serum IGF1 levels and either serum GH<0.3 µg/L (OGTT) or random serum GH<1 µg/L; or mean serum Growth
Hormone Day Curve (GHDC) <1 µg/L (The Endocrine Society
Guidelines for Acromegaly 1 ). As this resulted in the exclusion of 33% of the patients in the analysis, we have also used (b) "pragmatic control" where data on only either serum IGF1 or GH were available, due to the fact that some centres only perform IGF1 levels annually, or historically where GH levels only were used. Clinical practice is to review and where possible wean off GH-lowering (or opposing) medication. Since this may result in fluctuations in disease control, the first time a patient achieves biochemical control after STRS while on medication is defined as "control on medication," and the first time a patient achieves biochemical control off medication we defined as "control off medical treatment.".
As a National referral centre, our patients are followed up at other regional endocrinology units with varying biochemistry laboratories.
In the light of this, the local assay, age-and sex-matched serum IGF1
value ranges were used for the analysis. Normal ranges are provided in an online supplementary data set (Supporting Information Table   S1 ). For historical GH results recorded as miU/L, a conversion was performed (dividing by 3) to generate equivocal µg/L values. 4 To allow comparison across assays and over time, GH and IGF1 values were also recorded as a multiple above the upper limits of the local reference range at baseline and follow-up.
| Gamma knife treatment protocol
The technique used at our centre has been previously described. 5, 6 Treatment is performed over a single day, which involves frame fit- 
| Data management
A pragmatic approach was taken to assess the date of onset of hypopituitarism. The initiation of a new hormone replacement medication was taken as the first date at which hypopituitarism was confirmed.
The medication chosen would denote the appropriate axis of pituitary dysfunction. Due to the length of follow-up and retrospective nature of study, exact dates were not always available for onset of GH control or morbidity. Where data did not specify the exact date, but provided the year, the date allocated was the anniversary of the patient's STRS treatment. Association of Anaesthesiology (ASA) grade was used as a proxy for premorbid state and was obtained from documented co-morbidities at the time of gamma knife treatment.
| Statistical analysis
All statistics and graphs have been generated using graphpad prism 
| RE SULTS
| Biochemical control
One hundred and eighteen patients were treated for acromegaly with STRS at our centre between 1985 and 2015. Of these, twenty received primary STRS, with median age 54.5 years, and median follow-up of 166.5 months. Indications for primary STRS and treatment plans varied over this period, with a median marginal dose of 27.5 Gy (Table 1) . Of those deemed medically unfit, all were ASA-3
and had the following co-morbid conditions: (a) cardiomyopathy;
(b), ischaemic heart disease and aortic and mitral valve disease; and (c) carotid aneurysm. The mean age of patients for whom reasons were not given for primary gamma knife treatment was 47 years.
Of the 12 patients for whom full data were available that allowed assessment of control based on ES guidelines, at 20 years, 100% had full control when on medication, and 75% off medication (Figure 1 ).
Time for 50% to achieve guideline-based control on medication was 3 years, and 7.4 years off medication. Of note, of the 12 patients with both GH and IGF1 results, a discrepancy between these two tests reporting within normal limits was seen in 42% (5/12). In 3 patients where their last follow-up bloods were pre-2006, IGF1 values were normal, with abnormal GH values. In the two patients being tested in 2015, the GH results were normal, but IGF1 levels were outside of the normal range.
Eight patients could not be assessed by these stringent criteria.
Consequently, all patients were analysed as per "pragmatic control" criteria. Of these eight, only two were based on GH levels alone (there two patients were treated with STRS in 1986 (now deceased) whose last biochemical tests were performed in 1987 and 1996, respectively).
Time for 50% of the entire cohort to achieve "pragmatic control" was 3 years. At final follow-up, 95% (19/20) of the cohort achieved pragmatic control on medication; 31%, 43% and 71% had achieved "pragmatic control" off medication at 3, 7 and 20 years, respectively.
There was a trend towards higher doses being associated with faster control: "guideline-based" control (P = 0.02) and "pragmatic" control (P = 0.06). The effect was lost when using control on medication. No correlation was seen between cavernous sinus invasion and time to control. The pre-STRS GH and IGF-1 multiple of the upper normal limits value positively correlated with time for "guideline-based" control (P = 0.7) and pragmatic control (P = 0.006).
| Morbidity and mortality
During the 30-year follow-up, 7 patients died at a median age of 65 years. There were no STRS-related deaths, but all except one death (oesophageal cancer) were related to their acromegaly. There were no cases of ophthalmoplegia (despite 45% of radiation plans involving cavernous sinus). There were no cases of stroke. Failure to control GH levels or symptoms resulting in subsequent transsphenoidal surgery occurred in 15% (3/20), but there were no cases of secondary anterior skull base lesions, and no patient required a second STRS treatment (Table 1) . One patient experienced visual loss 8 months after STRS, which was performed in 1987 with CT rather than MRI-guided treatment. Sub-analysis showed no correlation between dose received or cavernous sinus invasion with the onset of hypopituitarism. 
| Hypopituitarism
| Tumour control
| Discussion
This is the first cohort of patients specifically analysed following treatment with primary STRS for acromegaly, with the longest follow-up period to date (median 166.5 months). We report outcomes on twenty patients from a series of 118, over a period of 30 years. The reasons given for primary STRS in our group are incomplete due to the retrospective nature of this study (Table 1) ; however, other groups have described patient preference as a major reason for primary STRS. 7 Our GH control data are comparative to other studies. However, no group has published control rates for a group of patients solely treated with primary STRS. The disparity seen between rates of "guideline control" off medication when compared to the Virginia group 8 may be explained by this difference. They included only two patients treated with primary STRS. It has been shown previously that transsphenoidal surgery and STRS are superior to STRS. 9 Within the constraints of these comparisons, we still show control rates similar to other published cohorts (Table 2) . It is important to note that more widespread use of medical therapy for acromegaly has led to a greater proportion of medically resistant patients being referred or selected for STRS. Our data can be compared witha UK acromegaly series of 656 patients who received fractionated ("conventional") radiotherapy (463 after TSS: 193 (33%) as a primary treatment). In that series where IGF-1 data were available, normalization off medication was seen in 38% at 2 years, 50% at 5 years, 63% at 10 years and 55% at 20 years. 11 Although the studies are not directly comparable, it appears that STRS as a primary treatment may not result in faster initial biochemical control compared to conventional radiotherapy, but at 20 years of follow-up, the rates of control are higher at 71% compared to 55%, respectively. One potential explanation is the differing doses used, but the single dose vs fractionation may also play a role.
Similar to fractionated radiotherapy, those with more severe disease in our study take longer to achieve control after STRS, in keeping with other studies . 2, 9, [12] [13] [14] Whilst the Pittsburgh group found a negative association between cavernous sinus infiltration and the rate of control using a multivariate analysis in a cohort of 40 patients, of whom 6
were treated with primary STRS, 7 we did not observe such an effect.
The differences may relate to the numbers treated or other factors.
Although there is variability in IGF1 assays over time, and the varying methods of quantifying GH control, we have aimed to provide the best possible analysis given the retrospective and multi-site nature of the data (raw data are provided in Supporting Information Table S1 ).
Rates of hypopituitarism post-STRS of pituitary fossa have progressively increased with length of follow-up from 0% to 58%. 12, 15 New-onset endocrinopathy secondary to STRS has previously been described as long as 160 months after treatment. 15 In another series where STRS was used post-craniotomy, 2% of patients had tumour growth, but only in regions not targeted by STRS, otherwise 46% of patients showed tumour reduction and 52%
showed tumour control. 13 Ronchi et al found a significant negative correlation between GH levels at the time of STRS and the probability of tumour shrinkage. This was independent of medication being stopped at time of treatment. 12 Our data support previous findings on tumour growth control even when using STRS as primary therapy. TA B L E 2 Comparison with other series using STRS for the treatment of acromegaly: Case series are listed in order of follow-up length. There is a trend to longer follow-up and higher remission rates GH, growth hormone; IGF-1, insulin-like growth factor 1; STRS, sterotactic radiosurgery.
a "Pragmatic control" was defined as GH<2.5 and IGF1 normal values or IGF-1 normalized alone; we categorized "pragmatic" control to be normal IGF-1 or GH<1. 3 of 20 patients had GH>2.5 while they had normal IGF1 values, but there was only 1 patient for whom the GH remained above 2.5 during our follow-up period.
The morbidity for STRS is low, but we acknowledge this is a small cohort to capture true risk rates. The only visual acuity loss was from a patient treated with CT-guided planning. All patients have undergone MRI-guided gamma knife treatment (since 1993).
Importantly, we did not observe any strokes in this cohort of primary STRS.
This study gives evidence for the efficacy of STRS in the treatment of appropriately selected GH-secreting pituitary adenomas.
While TSS will provide immediate GH control in many cases, if this is precluded by patient preference or other factors, then STRS offers a useful long-term strategy when accompanied by initial medical management.
The main limitations of this analysis is the retrospective review of recorded data. We were unable to fully explain why primary STRS was selected as the treatment of choice in 8 patients. In addition, it is impossible to have completely consistent biochemical analyses over a 30-year period. Control criteria changed during this period. We have taken the raw biochemical data from multiple regional centres and attempted to apply modern criteria to this data so as to deduce rates of biochemical control. Diagnosis of hypopituitarism was based on the active prescription of hormone replacement medication, as such this may under-diagnose disease, but does reflect a real-life assessment of where intervention was required. The strengths of our study include the 30 years of follow-up, which few centres across the world can match.
In conclusion this is the first report to selectively analyse patients who have undergone primary STRS for acromegaly. Whilst morbidity from STRS is low and time to biochemical control proportional to initial disease activity, there is significant latency to biochemical control and new-onset hypopituitarism. Accordingly, we advise very long-term follow-up for all patients who have undergone gamma knife treatment for acromegaly. STRS has shown good long-term efficacy providing initial control can be afforded by optimal medical management. While TSS remains best practice, STRS offers an alternative for those in whom surgery is not an option. Data from this cohort can be used to counsel patients and guide clinicians where primary STRS is being considered for the treatment.
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